Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

It has been just over a year since Latigo Biotherapeutics emerged from stealth mode with $135 million in Series A financing. Now, the Thousand Oaks-based has tacked on another $150 million to its ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

Latigo Biotherapeutics raises $150M Series B to advance Nav1.8 inhibitors for pain, competing with Vertex's Journavx.

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its Na v 1.8 inhibitors, which are being developed as non-opioid treatments ...

THOUSAND OAKS, Calif., March 17, 2025 /PRNewswire/ -- Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain ...